肝癌介入治疗中血清miR-122表达及其临床意义探讨

Expression and significance of serum miR-122 in hepatocellular carcinoma patients treated by transcatheter arterial chemoembolization

目的:研究肝癌患者血清miR-122在介入治疗过程中的表达及其临床意义。方法:提取血清中总RNA,利用荧光定量PCR方法检测29例肝癌患者血清中miR-122在肝动脉灌注栓塞(TACE)治疗前、后的表达情况。SPSS 16.0软件进行统计分析。结果:在29例肝癌患者血清中,介入治疗前后两次抽血平均间隔为8d,miR-122的表达水平在介入治疗后较介入治疗前有所降低,为治疗前的0.75倍(0.69～0.80倍),差异具有统计学意义,t=-2.326,P=0.027。29例肝癌患者介入治疗前血清miR-122的表达水平与年龄(t=-2.061,P=0.049)、AFP(t=3.370,P=0.002)和肿瘤直径(t=-2.077,P=0.047)显著相关,而与性别、巴塞罗那分期、Child-Puge分期、复发和多发因素均无关,P>0.05。结论:TACE治疗可引起肝癌患者血清中miR-122的表达降低,且miR-122的表达与患者年龄、血清中AFP的水平和肿瘤直径密切相关。

OBJECTIVE： To evaluate the expression of serum miR-122 in patients with hepatocellular carcinoma preand post-transcatheter arterial chemoembolization （TACE） treatment, as well as to assess the significance. METHODS： Total RNA （including microRNA） was extracted from the serum of patients with hepatocellular carcinoma. Serum miR- 122 expression was detected by reverse transcription and real-time PCR （RT-qPCR） in 29 HCC patients pre- and post- TACE,respectively. Clinicopathological data was retrieved and analyzed. SPSS 16.0 software was used to analysis the result. RESULTS： The levels of miR-122 were reduced in the post-TACE serum samples,which was 0. 75（0. 69-0. 80） fold of that of pre-TACE samples （t= -2. 326 ,P=0. 027）. Additionally,expression of serum miR-122 in HCC was correlated with age （t=-2. 061,P=0. 049）,AFP （t=3. 370,P=0. 002） and tumor diameter （t=-2. 077,P=0. 047）. It was not correlated with other factors such as gender,Barcelona Clinic Liver Cancer （BCLC） stage, Child-Puge stage, recurrence and multiple lesions （P〈0.05）. CONCLUSION： TACE treatment can cause reduced expression of miR-122 in the serum of HCC patients.